Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 7/20 | 0.56 |
| ▸ | DRD2 | P14416 | 6/20 | 0.56 |
| ▸ | DRD3 | P35462 | 6/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1328012 | 0.88 | HTR7 (0.47) | DRD4DRD2HTTPOLBNPSR1 | |
| SCHEMBL1328672 | 0.83 | DHFR (0.48) | DRD4DRD2DRD3ALDH1A1KDM4E | |
| SCHEMBL1329014 | 0.80 | C5AR1 (0.45) | DRD4DRD2ALDH1A1KDM4EKMT2A | |
| SCHEMBL2141586 | 0.79 | C5AR1 (0.43) | ALDH1A1KDM4EKMT2AMEN1POLB | |
| SCHEMBL2137925 | 0.79 | C5AR1 (0.43) | ALDH1A1KDM4EKMT2AMEN1POLB | |
| SCHEMBL1327929 | 0.79 | HTR7 (0.49) | DRD4DRD2ALDH1A1KDM4E | |
| SCHEMBL1328115 | 0.78 | DCTPP1 (0.53) | DRD4DRD2ALDH1A1KDM4ETSHR | |
| SCHEMBL1329564 | 0.77 | C5AR1 (0.42) | ALDH1A1KDM4EPOLB | |
| SCHEMBL1328958 | 0.77 | CYP2A13 (0.47) | ALDH1A1KDM4EKMT2AMEN1HTT | |
| SCHEMBL2140376 | 0.74 | C5AR1 (0.41) | DRD4DRD2DRD3ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110281837-A1 | 3-SUBSTITUTED-6-ARYL PYRIDINES | HUTCHINSON ALAN J (US) | 2011-11-17 | — | — | US | disclosed |
| US-7863454-B2 | 3-substituted-6-aryl pyridines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2011-01-04 | — | — | US | disclosed |
| US-20090176980-A1 | 3-Substituted-6-Aryl Pyridines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2009-07-09 | — | — | US | disclosed |
| US-7342115-B2 | Binding antagonist and arylpyridine for antiinflammatory agents, cardiovascular disorders and antagonist or agonist and for immunology | NEUROGEN CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281837-A1 | 3-SUBSTITUTED-6-ARYL PYRIDINES | C3AR1, C5AR1, C5AR2 | DRD4 1071/4885DRD2 879/4885DRD3 878/4885 |
| US-20090176980-A1 | 3-Substituted-6-Aryl Pyridines | C3AR1, C5AR1, C5AR2 | DRD4 1071/4885DRD2 879/4885DRD3 878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.